BioCentury on BioBusiness,
PBM Catamaran believes oral MS drugs could improve adherence; likes pricing
Pricing the MS orals
Monday, June 10, 2013
At least one pharmacy benefits
manager says the new oral multiple sclerosis drugs are starting off on the
right foot with smart pricing and the potential to improve adherence over
injectable standard of care. If they want to oust injectables from the top spot
on most formularies, the oral entrants will need to avoid steep price increases
and produce longitudinal data proving their benefits.
Oral drugs for relapsing-remitting multiple sclerosis (RRMS)
started to come online in October 2010 when Novartis
AG launched Gilenya fingolimod. Aubagio teriflunomide from Sanofi's
Corp. unit came next, in August 2012, followed this April by Tecfidera
dimethyl fumarate from Biogen
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]